Walleye Capital
NGM

Walleye Capital’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Walleye Capital’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,380
Closed -$10.6K – 6066
2023
Q4 		$10.6K Sell
12,380
-133,589
-92% -$117K ﹤0.01% 4555
2023
Q3 		$156K Sell
145,969
-100,994
-41% -$209K ﹤0.01% 3715
2023
Q2 		$640K Sell
246,963
-52,238
-17% -$186K ﹤0.01% 2243
2023
Q1 		$1.22M Buy
299,201
+74,884
+33% +$346K 0.02% 1020
2022
Q4 		$1.13M Buy
224,317
+209,648
+1,429% +$1.31M 0.02% 923
2022
Q3 		$192K Buy
+14,669
New +$222K ﹤0.01% 2142
2021
Q4 		– Sell
-22,368
Closed -$470 – 2386
2021
Q3 		$470 Buy
+22,368
New +$492K 0.01% 804

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's NGM Position: Q1 2024 in Review

Walleye Capital sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 12,380 shares — an estimated $10.6K sold.

Walleye Capital first reported a position in NGM in Q3 2021 and held it in 7 quarters. The position peaked at $1.22M in Q1 2023. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Walleye Capital reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Walleye Capital sold 12,380 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $10.6K.
  • Walleye Capital first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • Walleye Capital's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.22M in Q1 2023.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.